Several other research analysts also recently commented on the company. Zacks Investment Research cut shares of Omeros from a hold rating to a sell rating in a report on Saturday, November 16th. Maxim Group reissued a buy rating and issued a $25.00 price objective on shares of Omeros in a research note on Thursday, December 5th. HC Wainwright restated a buy rating and issued a $34.00 target price (down previously from $35.00) on shares of Omeros in a research report on Monday, December 2nd. ValuEngine lowered shares of Omeros from a hold rating to a sell rating in a research report on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Omeros in a research note on Wednesday, December 4th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $24.00.
NASDAQ:OMER opened at $13.64 on Friday. Omeros has a 12-month low of $12.52 and a 12-month high of $20.92. The stock’s 50 day moving average price is $13.97 and its two-hundred day moving average price is $15.71. The firm has a market capitalization of $678.31 million, a price-to-earnings ratio of -8.52 and a beta of 2.63.
Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.08. The company had revenue of $29.86 million during the quarter, compared to the consensus estimate of $27.19 million. Omeros’s revenue for the quarter was up 547.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.81) earnings per share. On average, equities research analysts forecast that Omeros will post -1.07 earnings per share for the current fiscal year.
In other news, Director Thomas J. Cable sold 10,000 shares of Omeros stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $13.16, for a total transaction of $131,600.00. Company insiders own 12.80% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in OMER. Charles Schwab Investment Management Inc. lifted its stake in Omeros by 1.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 268,719 shares of the biopharmaceutical company’s stock valued at $4,217,000 after buying an additional 3,725 shares during the period. Northern Trust Corp raised its holdings in shares of Omeros by 0.9% during the second quarter. Northern Trust Corp now owns 636,210 shares of the biopharmaceutical company’s stock valued at $9,982,000 after purchasing an additional 5,642 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Omeros by 13.9% during the second quarter. Parametric Portfolio Associates LLC now owns 39,578 shares of the biopharmaceutical company’s stock valued at $621,000 after purchasing an additional 4,842 shares during the period. United Capital Financial Advisers LLC raised its holdings in shares of Omeros by 2.5% during the second quarter. United Capital Financial Advisers LLC now owns 100,743 shares of the biopharmaceutical company’s stock valued at $1,581,000 after purchasing an additional 2,475 shares during the period. Finally, BlackRock Inc. boosted its position in shares of Omeros by 1.1% during the 2nd quarter. BlackRock Inc. now owns 3,858,463 shares of the biopharmaceutical company’s stock worth $60,539,000 after purchasing an additional 40,412 shares in the last quarter. 51.42% of the stock is currently owned by hedge funds and other institutional investors.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: What does the Dogs of the Dow mean?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.